Precision Medicine / Molecular Diagnostics / Oncology Genomics
Strategic Profile
Caris generates revenue through molecular profiling services to healthcare providers, hospitals, and oncologists, charging fees for tests that analyze tumor samples to identify genetic alterations and biomarkers, with key revenue streams including individual test payments, subscription models, and partnerships with pharmaceutical companies. The company is experiencing strong momentum with 2024 revenue of $412.26 million, a 34.67% increase compared to 2023, positioning itself as a high-growth precision medicine player in oncology.
Cyborg Score Rationale
Recent quarterly revenue of $181.4M exceeded expectations with 81% growth and strong profitability signals emerging, but the lack of current profitability and early-stage commercial payer conversations carry high risk. Stock volatility remains elevated due to execution risk.
Top Insights
Analyst consensus is "Strong Buy" with 12-month price target of $34.71, implying 55.58% upside from current levels
First post-IPO quarter materially exceeded consensus expectations with stronger pricing and volumes
Stock has declined sharply from all-time high of $42.50 in August 2025 to current levels, creating potential entry opportunity for believers
Revenue diversification through pharma partnerships, drug development, clinical trials, and academic institution collaborations provides multiple growth levers
Named Competitors
Personalis — Cancer genomics and molecular profiling
Editas Medicine — CRISPR-based therapeutics
Personal Genome Diagnostics — Tumor sequencing and cancer genomics
Recent Developments
(Feb 2026) Stock trading near 52-week lows following recent correction
(Q4 2025) Earnings beat expectations with 81% YoY revenue growth
(Aug 2025) All-time stock high of $42.50 reached during strong momentum period
Open the full interactive Caris Life Sciences, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.